tion was noted between the PAI-1 gene polymorphism and the Plasminogen activator inhibitor-1 gene polymorphism 4G/4G chronicity of the nephritis. genotype and lupus nephritis in Chinese patients.
up to 70% of patients with SLE develop lupus nephritis
This study was therefore conducted to determine the associa- [1] . The disease is multifactorial, with both environmen- with the development of lupus nephritis, while the DR3 in lupus patients and 0.59/0.41 in controls (P ϭ 1.000). No significant difference was noted in the genotype distribution and DR4 haplotypes are associated with high TNF-␣ between SLE patients with and without nephritis. However, production and are negatively correlated with lupus nelupus nephritis patients with the 4G4G genotype showed sigphritis [2]. The non-major histocompatibility complex nificantly heavier proteinuria (5.0 vs. 3.7 g/day; P ϭ 0.023) (MHC)-linked gene such as the IgG Fc receptor IIa polywhen compared with patients with 4G5G and 5G5G genotypes. Also, 73.3% patients with 4G4G had an activity index Ն8 morphism [3] has also been shown to be associated with versus 37.3% patients with 4G5G and 5G5G (P ϭ 0.003). the development and severity of lupus nephritis. The Extensive necrotizing lesions were seen in 51.7% patients with associations of different MHC and non-MHC genes with 4G4G as compared with 23.5% patients with 4G5G and 5G5G the development and severity of lupus nephritis suggest (P ϭ 0.014). The association of the 4G4G gene polymorphism that the disease is strongly genetically predisposed. with a higher nephritis activity and more severe necrotizing lesions persisted when only class III and class IV nephritis Endothelial cell activation and proliferation with subpatients were studied. On the other hand, no significant associasequent intravascular coagulation and fibrin deposition in the glomeruli are well-recognized features of active lupus nephritis [4] [5] [6] . Dysregulation in the coagulation and subsequent inflammatory cell infiltration. Glomerular fibrin deposit also has direct cytotoxic effect on mes-angial cells [8] . Recent studies indicate that endothelial structive uropathy were excluded. Case records of all patients were reviewed, and clinical information was re-cells play an important role in fibrinolysis by secreting both tissue-plasminogen activator (t-PA), which con-trieved from the case records. The information retrieved included clinical manifestation, organ involvement, pres-verts plasminogen to plasmin, and plasminogen activator inhibitor-1 (PAI-1), which regulates the activity of t-PA. ence of hypertension, initial renal function and proteinuria before initiation of imunosuppressive treatment, Endothelial cells produce large amount of PAI-1 in response to interleukin-1 (IL-1), TNF, and lipopolysaccha-treatment received, duration of follow-up, latest renal function, and history of renal relapse. Renal relapse is ride (LPS) stimulation. Increased PAI-1 expression in the glomerulus inhibits fibrin clearance at sites of coagu-defined as clinical evidence of relapse of lupus nephritis activity, namely rising proteinuria or serum creatinine lation and causes disease progression. Keeton et al demonstrated that female MRL/lpr mice developing early-with dropping complement levels with or without confirmation by renal biopsy and requiring stepping up or onset lupus nephritis with fibrin deposition show increased PAI-1 expression throughout the kidney, within both the addition of immunosuppressive therapy. the glomeruli, tubules, and vessels, while normal kidney Renal biopsy review showed no detectable level of PAI-1 [9] . Moreover, the level of PAI-1 expression is correlated with the severity Lupus nephritis was classified according to World Health Organization (WHO) classification [15] : class I, normal of lupus nephritis [9], suggesting that this important inhibitor of fibrinolysis may indeed contribute to the glomeruli; class II, mesangial alterations (lupus mesangiopathy); class III, focal segmental glomerulonephritis pathogenesis and progression of lupus nephritis.
Recently, a single base pair guanosine insertion/dele-(with active necrotizing lesions and/or sclerosis); class IV, diffuse proliferative glomerulonephritis (with or without tion polymorphism has been identified in the promoter region of the PAI-1 gene, situated 675 bp upstream from segmental lesions); and class V, diffuse membranous glomerulonephritis. Specific histologic features were used the start of transcription [10, 11] , and shown to alter PAI-1 gene expression in response to acute phase stimu-to assess the severity of lupus nephritis, and a previously reported semiquantitative scoring system was used to lus or cytokine stimulation such as IL-1 and TNF through an altered affinity for an nuclear factor-B (NF-B)-like grade individual biopsy features as described later in this article [16] . The scoring system used a scale of 0, 1, 2, factor [12]. The insertion/deletion 4G/5G polymorphism has been shown to alter circulating PAI-1 activity in or 3 corresponding to absent, mild (in less than 25% of glomeruli), moderate (affecting 25 t o 50% of glomeruli), healthy individuals [12], in non-insulin-dependent diabetes mellitus (NIDDM) patients [13] , and in patients with or severe (affecting more than 50% of glomeruli), respectively, for each individual histologic feature. The first coronary heart disease [14] . Patients with the 4G4G genotype have the highest levels of PAI-1 activity, while renal biopsy of all nephritis patients before embarking on any immunosuppressive treatment was used for his-those with 5G5G genotype have the lowest plasma PAI-1 activity [12] [13] [14] . Therefore, our study investigated the tology review. The presence of six or more glomeruli was considered adequate for biopsy grading. Two pathol-effect of this single base pair insertion/deletion 4G/5G polymorphism of the PAI-1 gene on the development and ogists graded the biopsies independently without knowledge of the patients' clinical history, renal function, and severity of lupus nephritis. It also examined the effect of this polymorphism on the progression of lupus nephritis.
PAI-1 genotype. The average of the scores graded by the two pathologists was taken as the final score. Activity index. The activity index was defined as the METHODS sum of individual scores of the following features consid-Patient selection ered to represent measures of active lupus nephritis: endocapillary hypercellularity (score 0 to 3), cellular One hundred eighteen patients who fulfilled the American College of Rheumatology (ACR) Classification of crescent (score 0, 2, 4, 6), necrotizing lesion (score 0, 2, 4, 6), hyaline deposit and thrombi (score 0 to 3), interstitial SLE were recruited from the Prince of Wales Hospital in Hong Kong, and 103 healthy subjects were recruited inflammatory cells (score 0 to 3), and glomerular leukocytes (score 0 to 3). The maximum score was 24 points as controls. All study subjects, including SLE patients and healthy controls, were of Southern Chinese origin.
for the activity index. Chronicity index. This index consisted of the sum of SLE patients were divided into two groups, namely those with renal involvement (LNϩ) and those without renal the following features considered to represent measures of chronic irreversible lupus lesions: glomerular sclerosis involvement (LNϪ). Renal involvement was defined according to ACR criteria, namely, persistent proteinuria (score 0 to 3), fibrous crescents (score 0 to 3), tubular atrophy (score 0 to 3), and interstitial fibrosis (score 0 to Ͼ0.5 g/day or 3ϩ proteinuria on urine dipsticks with or without the presence of cellular casts. Patients with 3). The maximum score was 12 points for the chronicity index. diabetes mellitus, other coexisting renal disease, or ob- rated by gel electrophoresis in 2% agarose gel (GIBCO, Grand Island, NY, USA), which had been stained with ethidium bromide and viewed under ultraviolet irradiation. Each subject was classified into 4G4G, 4G5G, or 5G5G according to the presence of the 139 bp PCR product generated by the allele-specific primers ( Fig. 1 ). and 4G5G/5G5G genotypes were compared using the Mann-Whitney test. Chi-square analysis was used to compare the PAI-1 genotype distribution between SLE patients and healthy controls, and between LNϩ and Determination of PAI-1 4G/5G genotype LNϪ patients. Chi-square analysis was also used to com-Genomic DNA was extracted from peripheral blood pare the PAI-1 genotype distribution in relationship to leukocytes of all 118 SLE patients and 103 healthy conthe specific histologic grading of the severity of lupus trols by standard techniques. PAI-1 4G/5G promoter genephritis. Interobserver concordance of the different hisnotype polymorphism was determined by polymerase tologic features was assessed using value. Correlation chain reaction (PCR) amplification of genomic DNA of between proteinuria, activity index and chronicity intex all subjects using the allele specific primers, (1) insertion was tested using Spearman correlation. A level of P Ͻ 5G allele 5Ј-GTC TGG ACA CGT GGG GG-3Ј and (2) 0.05 was considered statistically significant. deletion 4G allele 5Ј-GTC TGG ACA CGT GGG GA-3Ј. Each in combination with a common downstream primer, RESULTS 5Ј-TGC AGC CAG CCA CGT GAT TGT CTA G-3Ј, PAI-1 gene polymorphism in SLE patients and gave rise to a 139 base pair DNA fragment. A control healthy controls upstream primer, 5Ј-AAG CTT TTA CCA TGG TAA CCC CTG GT-3Ј, was used as a positive control in the Table 4 . No significant in Table 2 . No significant difference was noted in the difference was noted in the gender distribution, age of sex distribution and age of onset of SLE between patients onset of SLE, ACR score at initial presentation, and the with and without lupus nephritis. The median duration duration of follow-up between patients of the 4G4G and of follow-up was 92 (48-139) months for those with lupus 4G5G/5G5G genotypes. Patients of the 4G4G genotype nephritis versus 73 (45-109) months for those without had significantly higher proteinuria (U prot ) on initial prelupus nephritis (P ϭ NS). No significant difference was sentation as compared with those of 4G5G/5G5G genonoted in the PAI-1 4G/5G genotype distribution between types [median (IQR) baseline U prot g/day, 4G4G ϭ 5.0 LNϩ (N ϭ 93) and LNϪ (N ϭ 20) patients (4G4G:
Statistical analysis
(2.9-7.6) vs. 4G5G/5G5G ϭ 3.7 (1.7-5.4), P ϭ 0.023; 4G5G:5G5G ϭ 36.6:45.1:18.3% LNϩ vs. 30.0:65.0:5.0% Table 4 ]. No significant difference, however, was noted LNϪ; P ϭ NS; Table 2 ). However, LNϩ patients had a in the baseline serum creatinine (S Cr ) [4G4G ϭ 91 significantly higher incidence of hypertension (51.1 vs.
(62-179) mol/L vs. 4G5G/5G5G ϭ 90 (68-120) mol/L, 5.0%, P ϭ 0.0001) and more frequent use of angiotensin-P ϭ NS] and creatinine clearance (C Cr ) [4G4G ϭ 67 converting enzyme inhibitor (ACEI; 42.6 vs. 0%; P ϭ (40-93) mL/min vs. 4G5G/5G5G ϭ 66 (45-83) mL/min, 0.0001) as compared with LN patients. Moreover, a sig-P ϭ NS] between patients of the 4G4G and 4G5G/5G5G nificant difference was noted in the choice of immunogenotypes. The 4G4G:4G5G:5G5G genotype distribusuppressive treatment between LNϩ and LNϪ patients.
tion was 30.8:46.2:23.0% for patients with baseline S Cr Ͻ Potent immunosuppressive treatment, including cyclo-130 mol/L as compared with 52.2:43.5:4.3% for patients phosphamide and cyclosporine with or without azathiowith baseline S Cr Ն130 mol/L (P ϭ 0.066). No significant prine, was used in 92.5% of LNϩ patients as compared difference was noted in the incidence of hypertension with 0% of LNϪ patients (P ϭ 0.0001). The PAI-1 genobetween patients with the 4G4G (52.9%) and 4G5G/ type distribution, however, showed no significant differ-5G5G genotypes (50.8%) (P ϭ NS). The type of immuence among the different WHO classes of lupus nephritis nosuppressive treatment received was also comparable (4G4G:4G5G:5G5G ϭ 26.3:63.2:10.5% class III vs. 40.7:
among patients of the 4G4G versus 4G5G/5G5G geno-40.7:18.5% class IV vs. 38.9:38.9:22.2% class V; P ϭ NS;
type (Table 4 ). However, a significantly greater propor- Table 3 ).
tion of patients of the 4G4G genotype (61.8%) were Lupus nephritis and PAI-1 gene polymorphism treated with ACEI as compared with patients of 4G5G/ 5G5G genotypes (30.5%, P ϭ 0.005). During the dura-The clinical and biochemical features of patients with lupus nephritis with 4G4G (N ϭ 34) versus 4G5G/5G5G tion of follow-up, 73.5% patients with the 4G4G versus 67.8% patients with the 4G5G/5G5G genotype had a 0.001). The degree of proteinuria also showed a signifirenal relapse (P ϭ NS).
cant correlation with activity index (r ϭ 0.514, P Ͻ 0.001) Renal biopsies of 81 patients (4G4G, N ϭ 30; 4G5G, and chronicity index (r ϭ 0.372, P Ͻ 0.001) for the entire N ϭ 36; 5G5G, N ϭ 15) with underlying lupus nephritis group of patients. were available for histology review. The remaining 12
Specific histologic features of lupus nephritis used to patients either had initial biopsies performed in other score activity index and chronicity index were compared hospitals or the biopsies were considered inadequate for between patients of 4G4G and 4G5G/5G5G genotypes histologic grading of disease activity. The activity index (Table 5 ). There was no significant difference in the of each individual patient was plotted in a dot column degree of hypercellularity, hyaline deposit, glomerular format, grouped according to the PAI-1 genotype (Fig. leukocytes, and interstitial inflammatory cell infiltration 2A). Overall, the activity index of patients with the 4G4G between nephritis patients with the 4G4G and 4G5G/ genotype was significantly higher compared with those 5G5G genotypes. However, 30% patients with the 4G4G with 4G5G/5G5G genotypes [median (IQR) activity ingenotype had Ն25% cellular crescents formation as comdex, 4G4G vs. 4G5G/5G5G ϭ 10 (5-13) vs. 7 (4-9), P ϭ pared with 13.5% patients with the 4G5G/5G5G geno-0.033; Table 4 ]. No significant difference, however, was types (P ϭ 0.086; Table 5 ). More important, patients of noted in the chronicity index between patients with the 4G4G genotype showed more extensive necrotizing 4G4G and 4G5G/5G5G genotypes [median (IQR) CI, lesions as compared with patients of the 4G5G/5G5G 4G4G vs. 4G5G/5G5G ϭ 2 (0-4) vs. 2 (0-3), P ϭ NS;
genotypes; necrotizing lesions were present in at least Table 4 ]. The activity index was Ն8 in 73.3% patients Ն25% of glomeruli in 51.7% patients with 4G4G versus with the 4G4G as compared with 37.3% patients with 23.5% patients with 4G5G/5G5G genotype (P ϭ 0.014; the 4G5G/5G5G genotypes (P ϭ 0.003; Table 5 ). The Table 5 ). On the other hand, the degree of glomerulochronicity index was Ն4 in 26.7% patients with the 4G4G sclerosis, fibrous crescents, tubular atrophy, and interstigenotype as compared with 23.5% patients with the tial fibrosis showed no significant difference between 4G5G/5G5G genotype (P ϭ NS; Table 5 ).
patients of the 4G4G and 4G5G/5G5G genotypes. The The activity index was plotted against the chronicity association of 4G4G gene polymorphism with higher index for each individual according to the PAI-1 genonephritis activity [median (IQR) activity index, 4G4G type result (Fig. 2B) . A significant correlation was noted vs. 4G5G/5G5G ϭ 10 (9-14) vs. 7 (6-11); P ϭ 0.001] and between activity index and chronicity index for patients more extensive necrotizing lesions (necrotizing lesions in with the 4G4G genotype (r ϭ 0.66, P Ͻ 0.001) and patients with the 4G5G/5G5G genotype (r ϭ 0.48, P Ͻ Ն25% of the glomeruli, 4G4G vs. 4G5G/5G5G ϭ 68.2% vs. 30.8%; P ϭ 0.007) persisted when only class III and pathologists were 0.863, 0.934, 0.950, 0.842, 0.914, 0.786, class IV nephritis patients were studied. 0.936, 0.882, 0.828, and 0.754, respectively, all of statisti-The values used to assess interobserver concordance cal significance with P Ͻ 0.001. of the different histologic features including endocapillary hypercellularity, cellular crescent, necrotizing lesion, DISCUSSION hyaline deposit, interstitial inflammatory cells, glomerular leukocytes, glomerular sclerosis, fibrous crescents, This study describes a novel association between the PAI-1 4G/5G gene polymorphism and lupus nephritis. tubular atrophy, and interstitial fibrosis between the two brin deposition in the intraglomerular capillaries and a Scale 0-2 is absent-mild, and 4-6 is moderate-severe. promotes further glomerular injury by causing capillary thrombosis with subsequent inflammatory cell infiltration [7] . There is evidence to suggest that dysregulation of the coagulation and fibrinolytic system may be impor-Lupus nephritis patients of the 4G4G genotype showed significantly heavier proteinuria and a higher activity tant mediators of glomerular injury in lupus nephritis [20, 21] . Indeed, studies in the murine model of lupus index than those of the 4G5G or 5G5G genotype. A significantly greater proportion of patients with the nephritis showed overexpression of the PAI-1 gene throughout the kidney, both within the glomeruli and in 4G4G genotype had an activity index score of Ն8 rather than Ͻ8. Indeed, a significant correlation was also noted tubules and vessels, while no detectable expression was noted in the normal kidney [9]. In addition, a decrease between the degree of proteinuria and activity index of the nephritis. The association between the 4G4G geno-in t-PA expression is demonstrated. These changes correlate not only with the development of lupus nephritis type and greater nephritis activity was even stronger when only class III and IV nephritis patients were stud-but also with the glomerular fibrin deposition in the murine nephritic kidney [22] [23] [24] . Moreover, the level ied. However, no significant difference was noted in the genotype distribution and allele frequency between SLE of PAI-1 expression appears to be correlated with the severity of the disease [9]. Taken together, these observa-patients and controls, or between patients with and without nephritis, or among patients with the different WHO tions suggest that overexpression of the PAI-1 gene promotes the formation of microthrombi and contributes to classes of lupus nephritis. There was also no association of the PAI-1 gene polymorphism with the chronicity of the progression of lupus nephritis. However, the exact role of PAI-1 in the formation of the nephritis.
Moreover, individual histologic features used to score necrotizing lesions remains to be determined. Although endothelial cells produce a large amount of PAI-1, stud-the activity index and chronicity index were further ex-ies showed that mice with LN showed high levels of type may be reflected by more severe proteinuria in PAI-1 mRNA at many sites of active disease, including patients of the 4G4G as compared with those of the endothelial cells in the glomerulus, glomerular crescents, 4G5G/5G5G genotypes. No association was noted, howand glomerular and tubular epithelial cells [9] . We postuever, between the PAI-1 gene polymorphism and chrolate that enhanced PAI-1 expression in the endothelial nicity of the nephritis or the susceptibility to renal flares. cells may be responsible for suppressing the fibrinolytic
We conclude that dysregulation in the coagulation and system locally within the renal vasculature, hence causing fibrinolytic pathway is important in mediating the activintravascular coagulation associated with lupus nephritis ity of lupus nephritis, and may be related to the underlyand necrotizing lesions. Studies of lupus nephritis in ing PAI-1 4G/5G genetic polymorphism. Further studies MRL/lpr mice showed that other cytokines, including are needed to determine the role of PAI-1 in the develop-TNF [25, 26] and transforming growth factor (TGF) [27] , ment of necrotizing lesions in the human model of lupus which induce PAI-1 gene expression, may account for nephritis. the more widespread expression of PAI-1 in other renal tissues.
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